Details of the Drug Formulations

General Information of Drug (ID: DM2EXC5)

• Drug Name: BOL-303259-X Drug Info
• Synonyms: Latanoprostene bunod; Latanoprostene bunod); NCX-116; PF-03187207; PF-3187207; BOL-303259-X1; NO donors (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer; Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb

Indication

Disease Entry	ICD 11	Status	REF
Open-angle glaucoma	9C61	Approved	[1]
Renal cell carcinoma	2C90	Phase 3	[2]

• Cross-matching ID:
  PubChem CID: 11156438
  CAS Number: 860005-21-6
  TTD ID: D05LQX
  VARIDT ID: DR00093
  ACDINA ID: D01200

Full List of Drug Formulations Containing This Drug

Latanoprostene Bunod 0.24 mg/ml solution

Company	Formulation ID	FDA Description
Bausch & Lomb orporated	F23208	Polysorbate 80; Glycerin; Edta; Water

References

• [1] Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 in Healthy Japanese Subjects.Adv Ther. 2015 Nov;32(11):1128-39.
• [2] ClinicalTrials.gov (NCT01895972) A Study Evaluating the Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Japanese Subjects With Open-Angle Glaucoma or Ocular Hypertension. U.S.National Institutes of Health.